Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 18/20 | 1.00 |
| ▸ | FYN | P06241 | 3/20 | 1.00 |
| ▸ | ABL1 | P00519 | 2/20 | 0.83 |
| ▸ | BCR | P11274 | 2/20 | 0.83 |
| ▸ | EGFR | P00533 | 1/20 | 0.77 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.77 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6382249 | 0.92 | SRC (0.86) | SRCFYNABL1BCREGFR | |
| SCHEMBL6380451 | 0.92 | SRC (0.86) | SRCFYNABL1BCREGFR | |
| SCHEMBL934766 | 0.92 | SRC (1.00) | SRCFYNABL1BCREGFR | |
| SCHEMBL5255537 | 0.91 | SRC (1.00) | SRCFYNABL1EGFRERBB2 | |
| SCHEMBL5251751 | 0.91 | SRC (1.00) | SRCFYNABL1EGFRERBB2 | |
| SCHEMBL6685924 | 0.88 | SRC (0.83) | SRCFYNABL1BCREGFR | |
| SCHEMBL6383141 | 0.87 | EGFR (1.00) | SRCFYNABL1BCREGFR | |
| SCHEMBL6380183 | 0.86 | SRC (0.81) | SRCFYNABL1BCREGFR | |
| SCHEMBL4453074 | 0.85 | MAP2K1 (0.78) | SRCFYNABL1BCREGFR | |
| SCHEMBL6684408 | 0.85 | SRC (0.76) | SRCFYNABL1BCREGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1744735-A2 | METHOD OF TREATMENT OF MYOCARDIAL INFARCTION | The Scripps Research Institute (US) | 2007-01-24 | — | — | EP | claimed |
| WO-2005089366-A2 | METHOD OF TREATMENT OF MYOCARDIAL INFARCTION | THE SCRIPPS RESEARCH INSTITUTE (US) | 2005-09-29 | — | — | WO | claimed |
| US-20040214836-A1 | Method of treatment of myocardial infarction | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2004-10-28 | — | — | US | claimed |
| EP-1975620-A2 | Three hybrid assay system | GPC Biotech AG (DE) | 2008-10-01 | — | — | EP | disclosed |
| EP-1744735-A2 | METHOD OF TREATMENT OF MYOCARDIAL INFARCTION | The Scripps Research Institute (US) | 2007-01-24 | — | — | EP | disclosed |
| WO-2005089366-A2 | METHOD OF TREATMENT OF MYOCARDIAL INFARCTION | THE SCRIPPS RESEARCH INSTITUTE (US) | 2005-09-29 | — | — | WO | disclosed |
| US-20040214836-A1 | Method of treatment of myocardial infarction | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2004-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040214836-A1 | Method of treatment of myocardial infarction | SRC, LCK, DSTYK | SRC 1/4885FYN 11/4885ABL1 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.